Y-mabs announces sale of priority review voucher

New york, dec. 28, 2020 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a definitive agreement to sell its priority review voucher (“prv”) to united therapeutics corporation (nasdaq: uthr), based on an agreed valuation of $105 million.
YMAB Ratings Summary
YMAB Quant Ranking